Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Pharmacology & Efficacy Studies Capabilities

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES.

Pharmacology & Efficacy Studies Capabilities

Pharmacology and Efficacy Studies for Advanced Therapeutics

CELL & GENE | RNA | BIOLOGICS

Pharmacology and efficacy evaluations for advanced therapeutics and complex biologics demand a tailored scientific strategy. A standard template does not exist for these programs; applying proven intelligence in pharmacology investigation design is what accelerates next-generation therapies toward regulatory submission. The objective is to generate definitive, reproducible data that characterizes the biological activity and therapeutic benefit of a candidate asset.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

A close-up of a Pall Corporation single-use bioreactor system in a cleanroom environment, showing the control panel, vessel with cell culture media, and tubing.

Defining Proof-of-Concept and Therapeutic Range

These investigations establish the foundational proof-of-concept and inform therapeutic range characterization for subsequent IND-enabling toxicology programs. Our approach is built on designing evaluations specific to the asset’s modality and target indication. This includes developing customized preclinical models that accurately reflect the intended human disease state and selecting endpoints that provide clear, quantifiable evidence of therapeutic effect.

Supported Therapeutic Modalities and Key Efficacy Endpoints

Our capabilities support a wide range of modalities:

  • Viral Vectors: Characterizing the efficacy of AAV-based platforms (e.g., AAV8, AAV9, engineered capsids) and lentiviral vectors by measuring transgene expression, functional correction, and biodistribution.
  • RNA Payloads & LNP Delivery: Assessing the functional activity of mRNA, siRNA, or gRNA delivered via lipid nanoparticle (LNP) systems, including protein expression levels and target gene knockdown.
  • Cell-Based Modalities: Evaluating the in vivo persistence, trafficking, and anti-tumor activity of CAR-T, CAR-NK, or TCR-T cell constructs.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

The Imperative of Translational Relevance in Model Systems

Selecting a translationally relevant biological system is a pivotal decision point. For programs involving complex immune responses or novel vector platforms, choosing a system with an immune profile that closely mirrors human biology is a key factor in generating predictive data. This focus on translational relevance informs the entire investigation, ensuring the generated data package is robust and applicable to human clinical development.

Bioanalytical Validation and Data Package for Regulatory Submission

Demonstrating a clear therapeutic benefit while establishing a favorable safety profile in relevant preclinical systems is the core output of this work (PMID: 35333110). All bioanalytical assays used to measure endpoints are developed and qualified in a phase-appropriate manner to ensure data integrity. This rigorous, data-driven process minimizes clinical risk and builds a robust data package for successful regulatory interactions.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities